Mitotech S.A. is proud to co-author two poster presentations at ARVO 2016 held in Seattle, WA May 1-5.
"This is our second consecutive year co-presenting at ARVO,” said Natalia Perekhvatova, Chief Executive Officer of Mitotech S.A. “Last year we presented results of our Phase II clinical study of SkQ1 ophthalmic formulation Visomitin® in dry eye patients. That presentation was very well received by ARVO attendees back in 2015. At that same event, our collaborators at Mount Sinai School of Medicine also presented their in vitro findings highlighting SkQ1 suppressing ocular inflammation. This year the group from Mount Sinai School of Medicine will present positive results of a corneal wound healing study involving SkQ1. The second 2016 poster presented by Ora, Inc. will focus on SkQ1 reducing post-operative ocular inflammation – another promising ophthalmic indication in Mitotech's clinical development pipeline. Mitotech has established a strong development pipeline in ophthalmic indications and being a leading meeting in ophthalmology ARVO has become one of key annual events for our company.”
About Mitotech S.A
Mitotech S.A. is a Luxembourg-based biotechnology company developing novel drugs for treatment of age-related disorders. The core technology behind Mitotech products is based on a novel class of small molecules – mitochondrial addressed antioxidants. Company's lead compound SkQ1 is being developed in several drug formulations covering a variety of therapeutic areas with major focus on ophthalmology and neurodegenerative diseases.